相似文献
1
From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses.
Vaccines (Basel). 2023 Jan 2;11(1):109. doi: 10.3390/vaccines11010109.
2
Leveraging Lessons Learned from Yellow Fever and Polio Immunization Campaigns during COVID-19 Pandemic, Ghana, 2021.
Emerg Infect Dis. 2022 Dec;28(13):S232-S237. doi: 10.3201/eid2813.221044.
3
Social Media Engagement and Influenza Vaccination During the COVID-19 Pandemic: Cross-sectional Survey Study.
J Med Internet Res. 2021 Mar 16;23(3):e25977. doi: 10.2196/25977.
4
[Consideration on implementation of co-administration of Seasonal Influenza and COVID-19 vaccines during pandemic in China].
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Feb 6;56(2):103-107. doi: 10.3760/cma.j.cn112150-20211203-01117.
5
Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19.
Expert Rev Vaccines. 2022 Jul;21(7):957-974. doi: 10.1080/14760584.2021.1903878. Epub 2021 Aug 25.
6
The race Against Time to Save Human Lives During the COVID-19 With Vaccines: Global Evidence.
Eval Rev. 2022 Dec;46(6):709-724. doi: 10.1177/0193841X221085352. Epub 2022 May 30.
7
Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines.
PLoS Negl Trop Dis. 2017 Apr 14;11(4):e0005544. doi: 10.1371/journal.pntd.0005544. eCollection 2017 Apr.
8
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Oct 10;43(10):1515-1544. doi: 10.3760/cma.j.cn112338-20220825-00734.
9
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.
10
Impact of the SARS-CoV-2 pandemic on vaccine-preventable disease campaigns.
Int J Infect Dis. 2022 Jun;119:201-209. doi: 10.1016/j.ijid.2022.04.005. Epub 2022 Apr 6.
引用本文的文献
1
Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos.
Vaccines (Basel). 2025 Jul 22;13(8):776. doi: 10.3390/vaccines13080776.
2
Impact of Extended Dosing Intervals and Ipsilateral Versus Contralateral Boosting on mRNA Vaccine Immunogenicity in Mice.
Vaccines (Basel). 2025 Mar 1;13(3):263. doi: 10.3390/vaccines13030263.
3
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.
Vaccines (Basel). 2024 Dec 16;12(12):1418. doi: 10.3390/vaccines12121418.
4
Pediatric Respiratory Hospitalizations in the Pre-COVID-19 Era: The Contribution of Viral Pathogens and Comorbidities to Clinical Outcomes, Valencia, Spain.
Viruses. 2024 Sep 25;16(10):1519. doi: 10.3390/v16101519.
5
A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination.
Vaccines (Basel). 2024 Sep 13;12(9):1050. doi: 10.3390/vaccines12091050.
6
Charge Variants Characterization of Co-Formulated Antibodies by Three-Dimensional Liquid Chromatography-Mass Spectrometry.
Biomolecules. 2024 Aug 13;14(8):999. doi: 10.3390/biom14080999.
7
Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.
Front Immunol. 2024 Jun 21;15:1376395. doi: 10.3389/fimmu.2024.1376395. eCollection 2024.
8
Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine.
Sci Rep. 2024 Feb 20;14(1):4204. doi: 10.1038/s41598-024-54421-1.
9
Combining COVID-19 and seasonal influenza vaccines together to increase the acceptance of newly developed vaccines in the Eastern Mediterranean Region: a cross-sectional study.
Ann Med. 2023;55(2):2286339. doi: 10.1080/07853890.2023.2286339. Epub 2023 Nov 29.
本文引用的文献
1
Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers.
Clin Microbiol Infect. 2023 May;29(5):635-641. doi: 10.1016/j.cmi.2022.12.008. Epub 2022 Dec 9.
2
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.
Science. 2022 Nov 25;378(6622):899-904. doi: 10.1126/science.abm0271. Epub 2022 Nov 24.
3
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline.
Viruses. 2022 Nov 10;14(11):2488. doi: 10.3390/v14112488.
4
A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core.
EBioMedicine. 2022 Nov;85:104297. doi: 10.1016/j.ebiom.2022.104297. Epub 2022 Oct 4.
5
Influenza.
Lancet. 2022 Aug 27;400(10353):693-706. doi: 10.1016/S0140-6736(22)00982-5.
6
Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.
Vaccine. 2022 Aug 26;40(36):5356-5365. doi: 10.1016/j.vaccine.2022.07.021. Epub 2022 Jul 26.
7
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
Vaccine. 2022 Aug 26;40(36):5322-5332. doi: 10.1016/j.vaccine.2022.07.033. Epub 2022 Jul 29.
8
Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector.
Vaccines (Basel). 2022 Jul 18;10(7):1142. doi: 10.3390/vaccines10071142.
9
Rational development of a combined mRNA vaccine against COVID-19 and influenza.
NPJ Vaccines. 2022 Jul 26;7(1):84. doi: 10.1038/s41541-022-00478-w.
10
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses.
Vaccines (Basel). 2022 Jun 14;10(6):944. doi: 10.3390/vaccines10060944.
Zotero 插件